Rocket Pharmaceuticals, Inc. Warrant
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; l… Read more
Rocket Pharmaceuticals, Inc. Warrant (RCKTW) - Total Assets
Latest total assets as of September 2024: $393.69 Million USD
Based on the latest financial reports, Rocket Pharmaceuticals, Inc. Warrant (RCKTW) holds total assets worth $393.69 Million USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Rocket Pharmaceuticals, Inc. Warrant - Total Assets Trend (2019–2023)
This chart illustrates how Rocket Pharmaceuticals, Inc. Warrant’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Rocket Pharmaceuticals, Inc. Warrant - Asset Composition Analysis
Current Asset Composition (December 2023)
Rocket Pharmaceuticals, Inc. Warrant's total assets of $393.69 Million consist of 66.8% current assets and 33.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $25.15 Million | 4.4% |
| Goodwill | $39.15 Million | 6.9% |
Asset Composition Trend (2019–2023)
This chart illustrates how Rocket Pharmaceuticals, Inc. Warrant's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Rocket Pharmaceuticals, Inc. Warrant's current assets represent 66.8% of total assets in 2023, a decrease from 82.7% in 2019.
- Cash Position: Cash and equivalents constituted 9.9% of total assets in 2023, down from 49.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 8.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 6.9% of total assets.
Rocket Pharmaceuticals, Inc. Warrant Competitors by Total Assets
Key competitors of Rocket Pharmaceuticals, Inc. Warrant based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Rocket Pharmaceuticals, Inc. Warrant - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Rocket Pharmaceuticals, Inc. Warrant generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Rocket Pharmaceuticals, Inc. Warrant is currently not profitable relative to its asset base.
Rocket Pharmaceuticals, Inc. Warrant - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.05 | 13.35 | 17.69 |
| Quick Ratio | 6.05 | 13.35 | 17.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $201.77 Million | $ 413.39 Million | $ 369.89 Million |
Rocket Pharmaceuticals, Inc. Warrant - Advanced Valuation Insights
This section examines the relationship between Rocket Pharmaceuticals, Inc. Warrant's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 2.6% |
| Total Assets | $566.34 Million |
| Market Capitalization | $160.50 USD |
Valuation Analysis
Below Book Valuation: The market values Rocket Pharmaceuticals, Inc. Warrant's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Rocket Pharmaceuticals, Inc. Warrant's assets grew by 2.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Rocket Pharmaceuticals, Inc. Warrant (2019–2023)
The table below shows the annual total assets of Rocket Pharmaceuticals, Inc. Warrant from 2019 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $566.34 Million | +2.63% |
| 2022-12-31 | $551.81 Million | +11.02% |
| 2021-12-31 | $497.02 Million | -15.88% |
| 2020-12-31 | $590.82 Million | +58.77% |
| 2019-12-31 | $372.12 Million | -- |